• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Merck & Company Inc.

    6/25/24 1:38:29 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRK alert in real time by email
    11-K 1 a11-k_msdemployeestockpurc.htm 11-K MSD EMPLOYEE STOCK PURCHASE AND SAVINGS PLAN Document



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM 11-K
    FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS
    Pursuant to Section 15(d) of the Securities Exchange Act of 1934
    (Mark One)
    x    ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2023
    OR
    ¨    TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from                      to                     
    Commission File Number: 1-06571
    Employer Identification Number: 22-1918501
    Plan Number: 004
    MSD EMPLOYEE STOCK PURCHASE AND SAVINGS PLAN
    (Full title of the plan)
    MERCK & CO., INC.
    (Name of issuer of the securities held pursuant to the plan)
    126 East Lincoln Avenue
    Rahway, New Jersey 07065
    (Address of principal executive office)
     



    MSD Employee Stock Purchase and Savings Plan
    Index
    Page(s)
    Report of Independent Registered Public Accounting Firm
    1
    Financial Statements:
    Statements of Net Assets Available for Benefits as of December 31, 2023 and 2022
    2
    Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2023
    3
    Notes to Financial Statements
    4-11
    Supplemental Schedule*:
    Schedule H, Line 4i – Schedule of Assets (Held at End of Year)
    12
    Signature
    13
    Exhibit Index
    14
    Exhibit 23 - Consent of Independent Registered Public Accounting Firm
    15
     *    Other schedules required by Section 2520.103-10 of the Department of Labor Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 are omitted because they are not applicable.



    imagea.jpg

    Report of Independent Registered Public Accounting Firm

    To the Administrator and Plan Participants of MSD Employee Stock Purchase and Savings Plan

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of MSD Employee Stock Purchase and Savings Plan (the “Plan”) as of December 31, 2023 and 2022 and the related statement of changes in net assets available for benefits for the year ended December 31, 2023, including the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2023 and 2022, and the changes in net assets available for benefits for the year ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Information

    The supplemental Schedule H, Line 4i – Schedule of Assets (Held at End of Year) as of December 31, 2023 has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental schedule is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental schedule reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedule. In forming our opinion on the supplemental schedule, we evaluated whether the supplemental schedule, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental schedule is fairly stated, in all material respects, in relation to the financial statements as a whole.


    /s/ PricewaterhouseCoopers LLP
    New York, New York
    June 25, 2024

    We have served as the Plan’s auditor since 2002.





    PricewaterhouseCoopers LLP, PricewaterhouseCoopers Center, 300 Madison Avenue, New York, NY 10017
    T: (646) 471 3000, www.pwc.com/us

    -1-

    MSD Employee Stock Purchase and Savings Plan
    Statements of Net Assets Available for Benefits



    December 31,
    (in thousands)2023  2022
    Assets
        Investments
            Investment in Master Trust, at fair value$487,657 $453,257 
        Receivables
            Employer contributions244 218 
            Participant contributions816 725 
            Notes receivable from participants9,902 9,176 
                Total receivables10,962 10,119 
        Net assets available for benefits$498,619 $463,376 





















    The accompanying notes are an integral part of these financial statements.

    -2-

    MSD Employee Stock Purchase and Savings Plan
    Statement of Changes in Net Assets Available for Benefits


    Year Ended
    December 31,
    (in thousands)2023
    Additions to net assets attributed to
        Investment gain
            Plan interest in Master Trust investment gain$67,922 
        Interest income on notes receivable from participants546 
        Contributions to the Plan
            By participants21,803 
            By employer6,323 
                Total contributions28,126 
        Transfers in5 
                Total additions 96,599 
    Deductions from net assets attributed to
        Participant withdrawals(58,407)
        Administrative expenses(5)
        Transfers out(2,944)
                Total deductions(61,356)
                Net increase35,243 
    Net assets available for benefits
        Beginning of year463,376 
        End of year$498,619 

    The accompanying notes are an integral part of these financial statements.

    -3-

    MSD Employee Stock Purchase and Savings Plan
    Notes to Financial Statements
    1.Description of Plan
    The following description of the MSD Employee Stock Purchase and Savings Plan (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

    General
    The Plan is designed to provide a systematic means of saving and investing for the future as well as an easy and economical way for employees to become shareholders of Merck & Co., Inc. (“Merck” or the “Company”). Generally, any regular full-time, part-time, or temporary employee, who is a U.S. resident covered by a collective bargaining agreement providing for participation in this Plan as defined by the Plan document, is eligible to participate in the Plan on or after their date of hire or as otherwise provided pursuant to the applicable collective bargaining unit agreement. Merck is the Plan sponsor (the “Sponsor”).

    Participants direct the investment of their contributions into any fund investment option available under the Plan, including Merck common stock. The Plan offers a three-tiered approach to investing:

    *Retirement Portfolios - a custom set of target date retirement funds;
    *Core Funds - a selection of investment options (active and passive) that span a range of asset classes;
    *Fidelity Brokerage Link® - a self-directed brokerage account that provides access to more than 12,000 mutual funds.
    The Plan is administered by management committees appointed by the Company’s Chief Executive Officer, the Compensation and Management Development Committee of the Board of Directors of Merck or their delegates.
    The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).
    Master Trust
    The assets of the Plan are maintained, for investment purposes only, on a commingled basis with a portion of the MSD Puerto Rico Savings & Security Plan (the “Puerto Rico Plan”) and all of the assets of the Merck US Savings Plan in the Merck & Co., Inc. Qualified Plans Master Trust (the “Master Trust”). The plans own specific interests in the Master Trust assets.
    The portion of Master Trust assets allocable to each plan is based upon the participants’ account balances within each plan. Investment income for the Master Trust is allocated to each plan based on the specific investments held in the Master Trust.
    Contributions
    Participants may contribute between 2% and 25% of their base pay on a before-tax basis and up to 25% of base pay on an after-tax basis to the Plan, but the total of the before-tax and after-tax contributions cannot exceed a total of 25% of base pay. However, before-tax contributions cannot exceed the statutory limit ($22,500 in 2023). Upon reaching the statutory elective deferral limit, the participant may elect to suspend contributions for the remainder of the year or elect to continue on an after-tax basis.
    In addition, the Company makes matching contributions of $0.65 for every $1.00 of an employee's contributions, up to 6% of such employee's base pay (maximum match is 3.90% of base pay) per pay period (to the statutory limit). The combination of before-tax contributions, after-tax contributions and Company matching contributions may not exceed the statutory limit ($66,000 in 2023). Participant and Company matching contributions are invested according to a participant’s elections.
    In addition, the Plan permits unmatched before-tax “catch-up contributions” of up to the statutory limit ($7,500 in 2023) by participants who are at least age 50 by year-end.
    Participant Accounts
    Each participant’s account is credited with the participant’s contributions, the Company’s contributions and an allocation of Plan earnings. The allocation is based on participants’ account balances, as defined in the Plan document.

    -4-

    MSD Employee Stock Purchase and Savings Plan
    Notes to Financial Statements
    Vesting
    Participants are immediately vested in their contributions, all Company matching contributions, plus actual earnings thereon.
    Notes Receivable from Participants
    Participants may borrow from their account balances with interest charged at the prime rate plus 1%. Loan terms range from one to five years for a short-term loan or up to thirty years for the purchase of a primary residence and bear interest at rates that range from 4.25% to 10.00%. The minimum loan is $500 and the maximum loan is the lesser of (i) $50,000 less the highest outstanding loan balance(s) during the one year period prior to the new loan application date, or (ii) 50% of the participant’s account balance less any current outstanding loan balance(s) and defaulted loan amounts. Principal and interest are paid ratably through payroll deductions. Loan terms are grandfathered into the Plan in accordance with the legacy plan guidelines, including loan terms for participants that transferred into the Plan from a legacy plan.
    Payment of Benefits
    Participants are entitled to receive automatic, voluntary, in-service (which include hardship withdrawals), or mandatory distributions as provided in the applicable Plan provisions.
    Other Matters
    Transfers in and out during 2023 relate primarily to transfers between the Plan and the Merck US Savings Plan for employees who changed their status during the year.
    2.Summary of Accounting Policies
    Basis of Accounting
    The accompanying financial statements are prepared on the accrual basis of accounting.
    Use of Estimates
    The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities at the date of the financial statements. Management believes that these estimates are adequate. Actual results could differ from those estimates.
    Investment Valuation and Income Recognition
    All investments are recorded at fair value in the accompanying financial statements. Valuation of investments of the Plan represents the Plan’s specific interest in the Master Trust. The Plan’s investment in the Master Trust is stated at fair value and is based on the beginning of year value of the Plan’s interest in the Master Trust plus actual Plan contributions and specific investment income less Plan distributions, specific investment losses and allocated expenses.
    Purchases and sales of securities are recorded on a trade-date basis. Dividend income is recorded on the ex-dividend date. Interest income is recorded as earned. Realized gains and losses from security transactions are reported on the average cost method.
    Notes Receivable from Participants
    Notes receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Delinquent participant loans are reclassified as benefit payments based upon the terms of the Plan document. No allowance for credit losses has been recorded as of December 31, 2023 and 2022.
    Contributions
    Employee and Company matching contributions are recorded in the year in which participant compensation is earned.
    Payment of Benefits
    Benefits are recorded when paid.

    -5-

    MSD Employee Stock Purchase and Savings Plan
    Notes to Financial Statements
    Administrative Expenses

    Administrative expenses paid from plan assets include recordkeeping (for inactive participants), loan setup and other fees. Other administrative expenses are paid by the Company.
    Risks and Uncertainties
    The Plan provides for various investment options in investment securities. Investment securities, in general, are exposed to various risks and may decline in value for a number of reasons, including changes in prevailing interest rates and credit availability, increases in defaults, increases in voluntary prepayments for investments that are subject to prepayment risk under normal market conditions, widening of credit spreads and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants’ account balances and the amounts reported in the Statements of Net Assets Available for Benefits.
    3.Related-Party Transactions
    Contributions are held and managed by Fidelity Management Trust Company (“Fidelity” or the “Trustee”), which invests cash received, interest and dividend income and makes distributions to the participants. The Trustee also administers the participants’ payment of interest and principal on the notes receivable from participants. These transactions qualify as permitted party-in-interest transactions.
    Certain Plan investments are shares of registered investment companies (mutual funds) and common/collective trusts managed by the Trustee or its affiliates. Fidelity is the trustee as defined by the Plan and, therefore, these transactions qualify as party-in-interest transactions. The total market value of the Plan's portion of the investments managed by the Trustee was $31.1 million and $27.1 million at December 31, 2023 and 2022, respectively. During 2023, the Plan’s portion of interest and dividends, realized and unrealized gains from investments managed by the Trustee was $0.3 million, $1.1 million and $5.4 million, respectively.
    Merck also is a party-in-interest to the Plan under the definition provided in Section 3(14) of ERISA. Therefore, Plan transactions of Merck common stock qualify as party-in-interest transactions. The market value of the Plan’s portion of the investment in Merck common stock was $82.3 million and $94.4 million at December 31, 2023 and 2022, respectively. During 2023, the Plan’s portion of dividends, realized gains and unrealized losses from Merck common stock was $2.3 million, $3.6 million $5.1 million, respectively. The Plan’s portion of purchases and sales of Merck common stock during 2023 was $2.2 million and $5.7 million, respectively.
    4.Plan Termination
    Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. Upon termination of the Plan, each participant thereby affected would receive the entire value of his or her account as though he or she had retired as of the date of such termination.
    5.Tax Status
    The Plan obtained a tax determination letter from the Internal Revenue Service (“IRS”) dated March 4, 2015, indicating that the Plan had been designed in accordance with applicable sections of the Internal Revenue Code (“IRC”). The Plan has been amended since receiving the determination letter. However, the Sponsor believes that the Plan is designed and currently operates in compliance with the IRC. Therefore, no provision for income taxes has been made.
    Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. The Plan administrator has analyzed the tax positions taken by the Plan and has concluded that, as of December 31, 2023 and 2022, there are no uncertain tax positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions. The Plan administrator believes the Plan is no longer subject to income tax examinations for years prior to 2020.


    -6-

    MSD Employee Stock Purchase and Savings Plan
    Notes to Financial Statements

    6.Master Trust
    The net assets of the Master Trust and the Plan's interest are as follows:
    2023
    (in thousands)Master TrustMSD Employee Stock Purchase and Savings Plan Interest
    Registered investment companies (mutual funds)$859,826 $30,204 
    Common/collective trusts9,392,184 279,361 
    Equity securities1,966,941 71,899 
    Fixed income securities333,751 9,521 
    Self-directed brokerage accounts283,743 13,332 
    Merck common stock1,206,482 82,286 
    Accrued interest and dividends16,893 857 
    Other net assets/(liabilities)5,483 197 
    $14,065,303$487,657 
    2022
    (in thousands)Master TrustMSD Employee Stock Purchase and Savings Plan Interest
    Registered investment companies (mutual funds)$777,215 $28,491 
    Common/collective trusts7,515,493 232,509 
    Equity securities1,977,065 76,657 
    Fixed income securities343,618 10,901 
    Self-directed brokerage accounts214,838 9,663 
    Merck common stock1,281,137 94,373 
    Accrued interest and dividends14,819 849 
    Other net assets/(liabilities)(6,238)(186)
    $12,117,947$453,257

    -7-

    MSD Employee Stock Purchase and Savings Plan
    Notes to Financial Statements

    Total investment income (loss) of the Master Trust for the year ended December 31, 2023, is as follows:
    2023
    (in thousands)Master Trust
    Investment income
        Net appreciation$1,943,415 
        Interest and dividends151,999 
            Total investment income$2,095,414 


    7.Fair Value Measurements
    Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Entities are required to use a fair value hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:
    Level 1 – Quoted prices in active markets for identical assets or liabilities. The Master Trust's Level 1 investments primarily include registered investment companies (mutual funds), self-directed brokerage accounts and common stocks.
    Level 2 – Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Master Trust's Level 2 investments primarily include investments in certain fixed income investments such as government and agency obligations, corporate obligations and mortgage and asset-backed securities.
    Level 3 – Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Master Trust did not hold any Level 3 investments at December 31, 2023 and 2022.
    If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. There have been no changes in the valuation methodologies used at December 31, 2023 and 2022.
    Within the Master Trust, investments are recorded at fair value as follows:
    Registered Investment Companies (Mutual Funds)
    Registered investment companies (mutual funds) are valued at their respective net asset values. The net asset values are typically determined by the fund at the close of regular trading. Investments in registered investment companies (mutual funds) generally may be redeemed daily.
    Common/Collective Trusts
    The common/collective trusts are valued at their respective net asset values, as a practical expedient for fair value. The fair value of investments in the common/collective trusts are determined by their trustee. The Master Trust's investments in common/collective trusts generally may be redeemed daily.


    -8-

    MSD Employee Stock Purchase and Savings Plan
    Notes to Financial Statements
    Fixed Income Securities

    Fixed income securities, including U.S. government and agency obligations, corporate obligations and mortgage and asset-backed securities, are generally valued on the basis of valuations furnished by a pricing service approved by the Trustee or at fair value as determined in good faith by the Trustee and the Company. The Trustee has the discretionary authority to hire a pricing service to determine valuations using methods based on current market transactions, prices for comparable securities and various relationships between securities which are generally recognized by institutional traders.
    Self-Directed Brokerage Accounts
    Self-directed brokerage accounts are comprised of mutual funds, which are valued at the net asset value reported by the managers of the funds, typically determined at the close of regular trading.
    Equity Securities / Common Stocks
    Common stocks, for which market quotations are readily available, are generally valued at the last reported sales price on their principal exchange on the valuation date, or official close price for certain markets. If no sales are reported for that day, these investments are valued at the more recent of (i) the last published sale price or (ii) the mean between the last reported bid and asked prices for long positions, or at fair value as determined in good faith by the Trustee and the Company.


    -9-

    MSD Employee Stock Purchase and Savings Plan
    Notes to Financial Statements
    Master Trust Investments Measured at Fair Value
    Master Trust investments measured at fair value as of December 31, 2023 are summarized below:
    December 31, 2023
    Fair Value Measurements Using
    (in thousands)Quoted PricesTotal
    In ActiveSignificant
    Markets forOtherSignificant
    Identical ObservableUnobservable
    AssetsInputsInputs
    (Level 1)(Level 2)(Level 3)
    Investments in the Master Trust
    Registered investment companies$859,826 $— $— $859,826 
    Equity securities1,966,941 — — 1,966,941 
    Fixed income securities— 333,751 — 333,751 
    Self-directed brokerage accounts283,743 — — 283,743 
    Merck common stock1,206,482 — — 1,206,482 
    Investments measured within the fair value hierarchy$4,316,992 $333,751 $— $4,650,743 
    Common/collective trusts measured at NAV practical expedient (1)
    $9,392,184 
    Master trust investments at fair value$14,042,927 

    (1) Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The fair value amounts presented in this table also do not include the Master Trust's accrued interest and dividends or other net assets.

    The Plan's interests within the Master Trust as specifically identified in Note 6 are leveled in the same manner as the Master Trust investment categories presented above.

    -10-

    MSD Employee Stock Purchase and Savings Plan
    Notes to Financial Statements
    Master Trust Investments Measured at Fair Value
    Master Trust investments measured at fair value as of December 31, 2022 are summarized below:
    December 31, 2022
    Fair Value Measurements Using
    (in thousands)Quoted PricesTotal
    In ActiveSignificant
    Markets forOtherSignificant
    Identical ObservableUnobservable
    AssetsInputsInputs
    (Level 1)(Level 2)(Level 3)
    Investments in the Master Trust
    Registered investment companies$777,215 $— $— $777,215 
    Equity securities1,977,065 — — 1,977,065 
    Fixed income securities— 343,618 — 343,618 
    Self-directed brokerage accounts214,838 — — 214,838 
    Merck common stock1,281,137 — — 1,281,137 
    Investments measured within the fair value hierarchy$4,250,255$343,618$— $4,593,873
    Common/collective trusts measured at NAV practical expedient (1)
    $7,515,493
    Master trust investments at fair value$12,109,366 

    (1) Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The fair value amounts presented in this table also do not include the Master Trust's accrued interest and dividends or other net assets.

    The Plan's interests within the Master Trust as specifically identified in Note 6 are leveled in the same manner as the Master Trust investment categories presented above.

    8.Subsequent Events

    The Plan has evaluated subsequent events through the date the financial statements were issued and no events were noted which warrant adjustments to, or disclosure in the financial statements.

    -11-



    MSD Employee Stock Purchase and Savings PlanSchedule H
    Schedule H, Line 4i - Schedule of Assets (Held at End of Year)
    December 31, 2023
    (a)(b)(c)(d)   (e)
    Identity of Issue, Borrower, Lessor or Similar PartyDescription of Investment Including Maturity Date, Rate of Interest, Collateral, Par or Maturity ValueCostCurrent Value
    **  Master Trust  Investment in Master Trust***$487,656,775 
    *  Notes receivable from participantsInterest rates ranging from 4.25% to 10.00% and with maturities through 2052$9,901,823 
    Total$497,558,598 
    *     Denotes a party-in-interest to the Plan.
    **     There are certain investments within the Master Trust that are party-in-interest.
    ***     Cost information not required to be presented for participant directed investments.

    -12-



    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the Plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    MSD Employee Stock Purchase and Savings Plan
    By:
    /s/ Aaron Rosenberg
    Aaron Rosenberg
    Senior Vice President and Treasurer
    June 25, 2024


    -13-


    EXHIBIT INDEX
     
    Exhibit
    Number
    DocumentPage
    23Consent of Independent Registered Public Accounting Firm15
     

    -14-
    Get the next $MRK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRK

    DatePrice TargetRatingAnalyst
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    11/24/2025$125.00Equal Weight → Overweight
    Wells Fargo
    11/13/2025$105.00Sector Outperform
    Scotiabank
    10/13/2025$95.00Neutral
    Citigroup
    9/17/2025$90.00Buy → Hold
    Berenberg
    5/14/2025$84.00Buy → Neutral
    Citigroup
    More analyst ratings

    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Marketing Officer Guindo Chirfi sold $1,214,562 worth of shares (10,000 units at $121.46), decreasing direct ownership by 14% to 60,615 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/12/26 4:02:53 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive VP & President, MRL Li Dean Y sold $1,202,844 worth of shares (10,235 units at $117.52), decreasing direct ownership by 10% to 92,035 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/10/26 4:04:14 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Marketing Officer Guindo Chirfi sold $1,184,101 worth of shares (10,000 units at $118.41), decreasing direct ownership by 12% to 70,615 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/9/26 4:04:59 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    SEC Filings

    View All

    SEC Form 144 filed by Merck & Company Inc.

    144 - Merck & Co., Inc. (0000310158) (Subject)

    2/4/26 4:38:27 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck & Company Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Merck & Co., Inc. (0000310158) (Filer)

    2/3/26 6:38:40 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck & Company Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Merck & Co., Inc. (0000310158) (Filer)

    12/4/25 4:36:38 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Merck upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00

    2/13/26 8:35:09 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Merck from Peer Perform to Outperform and set a new price target of $135.00

    1/8/26 8:11:51 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Merck from Market Perform to Outperform and set a new price target of $130.00

    12/18/25 8:42:30 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

    KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors Approvals based on Phase 3 KEYNOTE-B96 trial that demonstrated the KEYTRUDA regimen reduced the risk of disease progression or death by 28% and reduced the risk of death by 24% compared to placebo plus paclitaxel with or without bevacizumab Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, with or

    2/11/26 6:45:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants

    Approval is based on the CLEVER and SMART Clinical Trial Results KIRKLAND, QC, Feb. 5, 2026 /CNW/ -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Health Canada has approved ENFLONSIA® (clesrovimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants born during or entering their first RSV season. ENFLONSIA® is a monoclonal antibody (mAb) that can help provide protection for up to five months—typical of an RSV season. The Health Canada approval marks an important

    2/5/26 7:05:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Financials

    Live finance-specific insights

    View All

    Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

    Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million WINREVAIR Sales Were $1.4 Billion CAPVAXIVE Sales Were $759 Million GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decli

    2/3/26 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck Announces Second-Quarter 2026 Dividend

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten

    1/27/26 3:07:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Feb. 3. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and C

    1/7/26 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/13/24 4:55:49 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/9/23 10:54:48 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

    SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)

    2/9/22 3:15:54 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care